Read more
Informationen zum Autor Dr. John Kelly , Senior Lecturer, Department of Pharmacology and Therapeutics, NUI, Galway, Ireland. Klappentext This title acts as a primer, giving students and newcomers to the field an opportunity to learn about the breadth of the CNS drug discovery. The book outlines the core processes in drug discovery and development for CNS disorders, from evaluating drugs for desirable efficacy, safety and pharmacokinetic features in preclinical (using in vitro and in vivo models) and clinical experimentation to identifying future drug targets. Containing up-to-date experimental evidence and detailing the main impediments in the pipeline of CNS drug discovery and development, this is a key reference for those involved in all stages of CNS drug discovery.Key Features:* Discusses in detail the key stages of CNS drug discovery, outlining the particular requirements and obstacles for CNS drugs* Addresses safety concerns and future drug targets* Provides succinct background information about the major CNS diseases* Examples of specific drugs are used throughout to describe the development of a new drug from conception to clinical use and post-market surveillance* Primary reasons for drug failure are given for each stage Zusammenfassung This title acts as a primer, giving students and newcomers to the field an opportunity to learn about the breadth of the CNS drug discovery. Inhaltsverzeichnis Acknowledgements. Preface. Abbreviations. 1 Introduction. 1.1 The global burden of CNS disease. 1.2 Assessment of the global burden of disease. 1.3 The prevalence of CNS disorders. 1.4 Disability due to CNS disorders. 1.5 Economic Costs. 1.6 Concluding comments. References. 2 An overview of the major CNS disorders. 2.1 Introduction. 2.2 Overview of psychiatric disorders. 2.3 Overview of neurological/neurodegenerative disorders. 2.4 Concluding comments. References. 3 Neurobiological substrates of CNS disorders. 3.1 Introduction. 3.2 Brief introduction to the principles of chemical neurotransmission. 3.3 Stages of chemical neurotransmission. 3.4 Approaches to investigating CNS alterations in CNS disorders. 3.5 Evidence for a neurobiological rationale for CNS disorders. 3.6 Concluding comments. References. 4 Current pharmacological targets. 4.1 Introduction. 4.2 Pharmacological treatments for depression. 4.3 Pharmacological treatments for schizophrenia. 4.4 Pharmacological treatments for anxiety disorders. 4.5 Pharmacological treatments for epilepsy. 4.6 Pharmacological treatments for Parkinson's disease. 4.7 Pharmacological treatments for Alzheimer's disease. 4.8 Concluding comments. References. 5 Premarketing efficacy evaluation. 5.1 Introduction. 5.2 Target identification. 5.3 Lead optimisation. 5.4 Target validation in animal models. 5.5 The use of genetically modified animals in CNS drug development. 5.6 A selection of animal models of psychiatric disease. 5.7 A selection of animal models of neurodegenerative disease. 5.8 Which models to choose. 5.9 Clinical trials that evaluate drug efficacy. 5.10 Specific drug profiles. References. 6 Pharmacokinetic considerations: Absorption, distribution, metabolism and elimination. 6.1 Introduction. 6.2 What are the 'ideal' pharmacokinetic properties for a CNS drug? 6.3 Absorption. 6.4 Distribution. 6.5 Metabolism. 6.6 Elimination. 6.7 Measurement of drug concentrations. 6.8 Factors that affect pharmacokinetics. 6.9 Allometric scaling. 6.10 Microdosing (Phase 0) Studies. 6.11 Dose...
